Acta Diabetologica

, Volume 48, Issue 2, pp 95–101

Mild hyperhomocysteinemia, C677T polymorphism on methylenetetrahydrofolate reductase gene and the risk of macroangiopathy in type 2 diabetes: a prospective study

  • Giuseppina Tiziana Russo
  • Antonino Di Benedetto
  • Domenico Magazzù
  • Annalisa Giandalia
  • Carlo Bruno Giorda
  • Riccardo Ientile
  • Marcello Previti
  • Enrico Di Cesare
  • Domenico Cucinotta
Original Article

Abstract

The role of hyperhomocysteinemia as a risk factor for diabetic long-term complications has not been sufficiently evaluated in prospective studies, considering specific correlates of homocysteine (tHcy) concentration and traditional cardiovascular disease (CVD) risk factors. Fasting tHcy, vitamin B12 and folate plasma levels, the common methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism, as well as clinical and lifestyle information were assessed in 216 type 2 diabetic patients attending two outpatient clinics, who had a follow-up evaluation at 65 ± 9 months for the incidence of macroangiopathy. At basal evaluation, mild hyperhomocysteinemia (tHcy ≥ 15 μmol/l) was diagnosed in 21.3% of participants. At follow-up, hyperhomocysteinemia and the distribution of MTHFR C677T genotype did not significantly differ according to the incidence of macroangiopathy. Multiple variables adjusted ORs (95% CI) for CVD associated with mild hyperhomocysteinemia were 1.01 (0.37–2.82); P > 0.05; those associated with MTHFR TT genotype were 0.46 (0.15–1.38); P > 0.05. Although the prevalence of hyperhomocysteinemia was higher in diabetic men (26.9%) than in women (16.1%; P > 0.05), similar results were also observed in a separate sex-analysis. At the multivariate analysis, including in the model other potential CVD risk factors, only creatinine clearance was a significant risk factor for the development of macroangiopathy. In this cohort of diabetic subjects, mild hyperhomocysteinemia and the MTHFR TT genotype are not significant risk factors for the development of macroangiopathy; impaired renal function was confirmed as a significant predictor of this complication.

Keywords

Homocysteine MTHFR Polymorphism Diabetes Macroangiopathy 

References

  1. 1.
    Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM et al (1998) Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 18:133–138PubMedGoogle Scholar
  2. 2.
    Elias AN, Eng S (2005) Homocysteine concentrations in patients with diabetes mellitus—relationship to microvascular and macrovascular disease. Diabetes Obes Metab 7:117–121PubMedCrossRefGoogle Scholar
  3. 3.
    Audelin MC, Genest J Jr (2001) Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 159:497–511PubMedCrossRefGoogle Scholar
  4. 4.
    Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J (2001) Determinants of plasma total homocysteine concentration in the Frammingham Offspring Cohort. Am J Clin Nutr 73:613–621PubMedGoogle Scholar
  5. 5.
    Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al (1995) A candidate genetic risk factor for vascular disease: a common mutation at the methylenetetrahydrofolate reductase. Nat Genet 10:111–113PubMedCrossRefGoogle Scholar
  6. 6.
    Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG, The MTHFR Studies Collaboration Group (2002) MTHFR 677 CT polymorphism and risk of coronary heart disease. JAMA 288:2023–2031PubMedCrossRefGoogle Scholar
  7. 7.
    Russo GT, Di Benedetto A, Giorda C, Alessi E, Crisafulli G, Ientile R et al (2004) Correlates of total homocysteine plasma concentration in type 2 diabetes. Eur J Clin Invest 34:197–204PubMedCrossRefGoogle Scholar
  8. 8.
    Passaro A, Calzoni F, Volpato S, Nora ED, Pareschi PL, Zamboni PF et al (2003) Effect of metabolic control on homocysteine levels in type 2 diabetic patients: a 3-year follow-up. J Intern Med 254:264–271PubMedCrossRefGoogle Scholar
  9. 9.
    Hoogeven EK, Kostense PJ, Jakobs C (1997) Does metformin increase the serum total homocysteine level in NIDDM? J Int Med 242:389–394CrossRefGoogle Scholar
  10. 10.
    Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP (2000) Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 23:1816–1822PubMedCrossRefGoogle Scholar
  11. 11.
    The Expert Committee on the Diagnosis of Diabetes Mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197Google Scholar
  12. 12.
    Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, Diabetes and Informatics Study Group (2008) Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. Diabetes Care 31:2154–2159PubMedCrossRefGoogle Scholar
  13. 13.
    The DAI Study Group (2004) Prevalence of coronary heart disease in a cohort of type 2 diabetic patients in Italy: the DAI study. Diabet Med 21:738–745CrossRefGoogle Scholar
  14. 14.
    Rose GA, Blackburn H (1968) Cardiovascular survey methods. Monogr Ser World Health Organ 56:1–188PubMedGoogle Scholar
  15. 15.
    Welch GN, Loscalzo J (1998) Homocysteine and atherothrombosis. N Engl J Med 338:1042–1050PubMedCrossRefGoogle Scholar
  16. 16.
    Ueland PM, Refsum H, Beresford SA, Vollset SE (2000) The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72:324–332PubMedGoogle Scholar
  17. 17.
    Araki A, Sako Y, Ito H (1993) Plasma homocysteine concentrations in Japanese patients with non insulin-dependent diabetes mellitus: effect of parenteral methylcobalamin treatment. Atherosclerosis 103:149–157PubMedCrossRefGoogle Scholar
  18. 18.
    Chico A, Perez A, Cordoba A, Arcelus R, Carreras G, De Leiva A et al (1998) Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 41:684–693PubMedCrossRefGoogle Scholar
  19. 19.
    Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ et al (2000) Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn study. Circulation 101:1506–1511PubMedGoogle Scholar
  20. 20.
    Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T (2004) Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med 140:94–100PubMedGoogle Scholar
  21. 21.
    Ndrepepa G, Kastrati A, Braun S, Koch W, Kölling K, Mehilli J et al (2006) A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease. Clin Chim Acta 373:70–76PubMedCrossRefGoogle Scholar
  22. 22.
    Selhub J (2006) The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J Nutr 136:1726S–1730SPubMedGoogle Scholar
  23. 23.
    Brattström L, Wilcken DEL (2000) Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 72:315–323PubMedGoogle Scholar
  24. 24.
    Passaro A, D’Elia K, Pareschi P, Calzoni F, Carantoni M, Fellin R et al (2000) Factors influencing plasma homocysteine levels in type 2 diabetes. Diabetes Care 23:420–421PubMedCrossRefGoogle Scholar
  25. 25.
    Russo GT, Friso S, Jacques PF, Rogers G, Cucinotta D, Wilson PW et al (2003) Age and gender affect the relation between methylenetetrahydrofolate reductase C677T genotype and fasting plasma homocysteine concentrations in the Framingham Offspring Study cohort. J Nutr 133:3416–3421PubMedGoogle Scholar
  26. 26.
    Arai K, Yamasaki Y, Kaijmoto YY, Watada H, Umayahara Y, Kodama M et al (1997) Association of methylenetetrahydrofolate reductase gene polymorphism with carotid arterial wall thickening and myocardial infarction risk in NIDDM. Diabetes 46:2102–2104PubMedGoogle Scholar
  27. 27.
    Hasegawa G, Obayashi H, Kamiuchi K, Nakai M, Kanatsuna T, Yamaguchi M et al (2003) The association between end-stage diabetic nephropathy and methylenetetrahydrofolate reductase genotype with macroangiopathy in type2 diabetes mellitus. Exp Clin Endocrinol Diabetes 111:132–138PubMedCrossRefGoogle Scholar
  28. 28.
    Sun J, Xu Y, Xue J, Zhu Y, Lu H (2005) Methylenetetrahydrofolate reductase polymorphism associated with susceptibility to coronary heart disease in Chinese type 2 diabetic patients. Mol Cell Endocrinol 229:95–101PubMedCrossRefGoogle Scholar
  29. 29.
    Mazza A, Motti C, Nulli A, Pastore A, Andreotti F, Ammaturo V et al (1999) Serum homocysteine, MTHFR gene polymorphism, and carotid intimal-medial thickness in NIDDM subjects. J Thromb Thrombolysis 8:207–212PubMedCrossRefGoogle Scholar
  30. 30.
    Scaglione L, Gambino R, Rolfo E, Lillaz E, Gai M, Cassader M et al (2002) Plasma homocysteine, methylenetetrahydrofolate reductase gene polymorphism and carotid intima-media thickness in Italian type 2 diabetic patients. Eur J Clin Invest 32:24–28PubMedCrossRefGoogle Scholar
  31. 31.
    The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354:1567–1577CrossRefGoogle Scholar
  32. 32.
    B-Vitamin Treatment Trialists’ Collaboration (2006) Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 151:282–287CrossRefGoogle Scholar
  33. 33.
    Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Raschetti R, Raschetti R, Raschetti R, Lombardo F, Diabetes, Informatics Study Group, Association of Clinical Diabetologists, Istituto Superiore di Sanità (2007) Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 30:1241–1247PubMedCrossRefGoogle Scholar
  34. 34.
    Cheng TY, Wen SF, Astor BC, Tao XG, Samet JM, Wen CP (2008) Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle-aged working population in Taiwan. Am J Kidney Dis 52:1051–1060PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Giuseppina Tiziana Russo
    • 1
  • Antonino Di Benedetto
    • 1
  • Domenico Magazzù
    • 2
  • Annalisa Giandalia
    • 1
  • Carlo Bruno Giorda
    • 3
  • Riccardo Ientile
    • 4
  • Marcello Previti
    • 1
  • Enrico Di Cesare
    • 1
  • Domenico Cucinotta
    • 1
  1. 1.Department of Internal Medicine, Policlinico Universitario “G. Martino” Via C. ValeriaUniversity of MessinaMessinaItaly
  2. 2.Department of Health Sciences, Unit of Medical Statistics and EpidemiologyUniversity of PaviaPaviaItaly
  3. 3.Metabolism and Diabetes UnitChieriItaly
  4. 4.Department of Biochemical SciencesUniversity of MessinaMessinaItaly

Personalised recommendations